Options Exercise: Janux Executive Sells 16,665 Shares for $501,000

Core Insights - The Chief Business Officer of Janux Therapeutics, Meyer Andrew Hollman, sold 16.87% of his direct holdings in a routine insider transaction, exercising stock options and selling shares for approximately $501,000 on October 28, 2025 [1][3][4]. Transaction Summary - The transaction involved the sale of 16,665 shares, valued at around $501,000, with a post-transaction holding of 82,139 shares worth approximately $2.44 million [2][5]. - The weighted average purchase price for the transaction was $30.06 [2]. Nature of the Transaction - This transaction was classified as a derivative-based event, where the executive converted stock options into cash without increasing his equity stake in the company [3]. Significance of the Sale - The shares sold represented a significant portion of Hollman's holdings, with the 16,665 shares accounting for 16.87% of his direct ownership prior to the transaction [4]. Post-Transaction Liquidity - After the transaction, Hollman retained 82,139 shares valued at approximately $2.44 million, indicating continued substantial ownership in the company [5]. Company Overview - Janux Therapeutics is an early-stage biotechnology company focused on developing innovative immunotherapies for cancer, utilizing proprietary platforms TRACTr and TRACIr [7]. - The company has a market capitalization of $1.64 billion and reported a net income of -$105.64 million [6]. Market Performance - As of October 28, 2025, the stock price was $30.06, reflecting a 1-year price change of -51.01% [6]. - The stock has shown significant volatility, with a recent crash of around 50% following disappointing clinical trial results [10].